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a  b  s  t  r  a  c  t
Interleukin  6  (IL-6)  and  tumor  necrosis  factor  alpha  (TNF)  are  proinﬂammatory  cytokines  that  play  a  crit-
ical  role  in inﬂammatory  bowel  disease,  as  well  as in  colorectal  tumorigenesis.  We  hypothesize  that  these
cytokines  modulate  the  expression  and  thus  activity  of  the  vitamin  D  system  in colonic  epithelial  cells.  We
treated  the  colon  cancer  cell line  COGA-1A  for 6, 12,  and  24 h  with  1,25-dihydroxyvitamin  D3 (1,25-D3),
IL-6,  TNF,  and  with  combinations  of  these  compounds.  Using  quantitative  RT-PCR,  we analyzed  mRNA
expression  of genes  activating  and  catabolizing  1,25-D3 (1-hydroxylase  (CYP27B1),  24-hydroxylase
(CYP24A1)),  expression  of several  vitamin  D target  genes,  as  well  as  expression  of  cyclooxygenase  2
(COX-2)  and  15-hydroxyprostaglandin  dehydrogenase.  As  expected,  treatment  with  1,25-D3 resulted  in
an upregulation  of CYP24A1,  whereas  expression  of CYP27B1  was  not  affected.  Treatment  with  TNFNF
L-6
YP24A1
RPV6
and  IL-6 led  to decreased  expression  of  the  vitamin  D  activating  enzyme  CYP27B1.  The  strong  inﬂamma-
tory  property  of  TNF  was  mirrored  by  its  activation  of  COX-2  and  inhibition  of prostaglandin  E2 (PGE2)
catabolism.  Interestingly,  expression  of the  calcium  ion  channel  TRPV6  was  markedly  decreased  by TNF.
We  conclude  from  these  results  that  the presence  of  proinﬂammatory  cytokines  might  impair  activation
of  1,25-D3,  limiting  its  anti-inﬂammatory  action.
This  article  is  part  of a Special  Issue  entitled  ‘16th  Vitamin  D  Workshop’.
© 2013  The  Authors.  Published  by Elsevier  Ltd.  All  rights  reserved.
ontents
1. Introduction  .  . . .  . .  .  . .  .  . . .  .  . . .  . . .  . . . .  . . .  .  . . .  .  . . .  .  . . . . . . . . . .  . . . . . . .  .  . . . . . . .  . . . .  . . .  . . .  . . . . . . .  . . . . .  . . .  . . . . .  . . .  . . .  . .  .  .  . . .  . . .  .  . . .  . .  .  . .  . . . . . . . . . . .  .  . .  . .  .  . .  .  . . 92
2.  Materials  and  methods  .  .  . . . .  . . .  .  . . . . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . . . .  .  . .  . . . .  .  . . . . . . .  . . .  . . .  . . . .  . . . . .  .  . . . . .  . . .  . . . .  . . . .  . . . . . . .  .  . . . .  .  .  . . .  .  .  .  .  . .  .  . . . .  . . . . .  .  .  . .  . .  92
2.1.  Cell  culture  . .  .  . . .  .  . . .  .  . . .  .  . . .  .  . . .  . . . .  . . .  .  . . .  .  . .  .  .  . . .  .  . . .  . . .  .  . . .  .  .  . . . . . . .  . .  . . .  .  . .  .  . . . .  . . . . . . . .  . . . . . . .  . . .  . . . . . . .  . . .  . . . .  .  . . . . . .  . . .  .  .  . . . .  .  . . . .  . . . .  .  92
2.2. RNA  extraction  and  reverse  transcription  (RT) . . .  .  . . . . . .  .  .  . . . . .  .  .  .  . .  . . .  . . . .  . . .  . . . . . . .  .  . . .  . . . .  .  . .  . . . .  .  .  . .  . . .  . .  . . .  . .  .  . . . .  . . . . . . . . . .  .  . .  .  . .  .  .  .  .  .  . 92
2.3.  Quantitative  real  time  RT-PCR  . . .  .  . . . . . . . . . . . . . . . . . . . . . .  . . .  . . .  . . .  .  . .  . . .  . . . . . . .  . . . . . . .  .  . . .  . . . .  . . .  . . . . .  . .  . . . .  . . . .  . . .  .  .  . . .  .  .  .  .  . .  .  . . . . . . . . .  .  . . .  . .  .  92
2.4.  Statistical  analysis .  . . . .  . . . .  . . .  .  . . .  .  . . . .  . . . .  . . .  . . . .  . . . .  . . .  . . .  .  . . . .  . .  .  .  . . . . .  . .  . . . . .  . . .  . . . . .  . . . . . .  . . . . . . .  .  . . . . . . .  . .  . . . . .  . . .  .  .  .  . . . .  .  . . . . .  . .  .  .  . . . .  .  .  92
3.  Results  . . .  . . .  . .  . .  .  . . . . .  . . .  .  . . .  . . . .  . . . .  .  . . .  .  . .  .  .  . .  .  .  . . .  . .  .  .  . . . . . . .  . . . . . . . .  . . .  .  . .  . . .  . . . . . . .  . . . . . . .  .  . . . . . .  .  .  . . .  . . . .  . . .  . .  .  .  . . . . . .  .  . .  . . . . . .  .  . . .  .  .  .  . . . . . .  . . . . 92
3.1.  Regulation  of  CYP24A1  and  CYP27B1  expression  by  1,25-D3, TNF,  and  IL-6  .  .  . . . . . . . . . . . . .  . . . .  .  . . . . . .  . . . . . . .  .  . . . .  .  .  .  . .  . . . . .  .  . . . . .  . . .  . .  .  .  .  .  92
3.2. Effect  of 1,25-D3,  IL-6,  and  TNF  on  expression  of the  vitamin  D  t
4.  Discussion  .  .  .  .  . . . . .  .  . . .  .  . . .  .  . . .  .  . . .  . . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . . . . .  .  . .  . . .  . . . .  .
Acknowledgements  .  .  . . . . . .  . . . .  . . .  . . . .  .  . . .  .  . .  .  .  . .  .  .  . . .  . .  .  .  . . . . . .  . . . . . . . .  .  . .
References  . .  .  . . .  . .  . . . . . . . . . . .  . . . .  . . .  .  . . .  .  . . .  . . . . . . . . . . .  . . . .  . . .  . . . .  . .  .  .  . . .  . . .
Abbreviations: IBD, inﬂammatory bowel disease; CYP24A1, 1,25-dihydroxyvitamin
ytochrome P450, family 3, subfamily A, polypeptide 4; TRPV6, transient receptor pote
inding protein 3; PGE2, prostaglandin E2; COX-2, cyclooxygenase-2; 15-PGDH, 15-hydr
 This is an open-access article distributed under the terms of the Creative Commons At
ny  medium, provided the original author and source are credited.
∗ Corresponding author at: Department of Pathophysiology and Allergy Research, Leitste
el.:  +43 1 40400 5123; fax: +43 1 40400 5130.
E-mail addresses: doris.hummel@meduniwien.ac.at (D.M. Hummel), irfete.fetahu@m
eresa.manhardt@meduniwien.ac.at (T. Manhardt), enikoe.kallay@meduniwien.ac.at (E. K
960-0760/$ – see front matter © 2013 The Authors. Published by Elsevier Ltd. All rights 
ttp://dx.doi.org/10.1016/j.jsbmb.2013.09.017arget  genes  CYP3A4,  TRPV6,  IGFPB3,  COX-2,  and  15-PGDH  .  . .  .  .  . .  .  . .  .  92
 . .  . .  .  . . . . . .  .  .  . . . .  . .  . . . .  . . .  . . . .  .  . . .  .  .  . .  . . .  .  .  . . . .  .  . . . .  .  . . .  .  .  .  . . . .  . . . .  . .  . . .  .  .  92
 . . . .  . .  . . . .  . .  . . . . .  . . .  . . . .  . . . .  . . . . . . .  . . . . . . . .  . .  . . . . . .  .  .  .  .  . . . . . .  .  . . .  .  . .  .  . . .  .  .  94
 .  . . .  . . . . . . . . . . . .  . . .  . . . .  .  . . . . . . . .  . . . . .  .  . . . .  . . .  .  . . .  . .  .  . . . .  .  .  . . . . . . . .  . .  . . .  .  . .  94
 D3 24-hydroxylase; CYP27B1, 25-hydroxyvitamin D3 1-hydroxylase; CYP3A4,
ntial cation channel, subfamily V, member 6; IGFBP3, insulin-like growth factor
oxyprostaglandin dehydrogenase.
tribution License, which permits unrestricted use, distribution and reproduction in
lle 3Q, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
eduniwien.ac.at (I.S. Fetahu), charlotte.groeschel@meduniwien.ac.at (C. Gröschel),
állay).
reserved.
9 hemis
1
d
m
C
r
g
e
i
f
t
o
D
a
p
p
v
e
t
6
o
o
T
a
2
2
e
p
t
c
t
2
I
I
G
t
R
(
2
d
g
M
h
a
[
(
f
f
C
C
C
r2 D.M. Hummel et al. / Journal of Steroid Bioc
. Introduction
The term inﬂammatory bowel disease (IBD) describes a set of
iseases characterized by chronic inﬂammation of the intestinal
ucosa. The two major forms of IBD are ulcerative colitis and
rohn’s disease [1]. The highest incidence rates of IBD have been
eported in the UK, northern Europe, and North America [2]. This
eographical distribution points toward an inﬂuence of sunlight
xposure on the prevalence of this disease.
The proinﬂammatory cytokines TNF and IL-6 play a crucial role
n IBD [3,4] and treatment with TNF-blockers is a standard therapy
or ulcerative colitis. Patients suffering from IBD have a higher risk
o develop colorectal cancer (CRC). In CRC, both TNF and IL-6 are
ften overexpressed [5,6].
Increasing evidence supports the preventive effect of vitamin
 on the development of IBD and CRC [7], but how inﬂammation
ffects the local vitamin D system in the colon is less known. In the
resent study, on the one hand, we examined the inﬂuence of two
roinﬂammatory cytokines on the expression of genes involved in
itamin D metabolism, such as CYP27B1, the vitamin D activating
nzyme [8], and CYP24A1, the vitamin D catabolizing enzyme. On
he other hand, we assessed whether treatment with TNF and IL-
 would impair the effect of 1,25-dihydroxyvitamin D3 (1,25-D3)
n different vitamin D target genes. We  have chosen CYP3A4 (one
f the crucial drug-metabolizing enzymes), the calcium channel
RPV6, and the insulin-like growth factor binding protein, IGFBP3,
ll well-known targets of 1,25-D3 [9–11].
. Materials and methods
.1. Cell culture
The adenocarcinoma cell line COGA-1A is derived from a mod-
rately differentiated pT3 colon tumor and was  characterized
reviously [6,12]. One week after conﬂuency, COGA-1A cells were
reated with 10 nM 1,25-D3, 100 ng/ml IL-6, 50 ng/ml TNF, or with
ombinations of these compounds for 6, 12, and 24 hours (h). Con-
rols were treated with PBS and 0.01% EtOH.
.2. RNA extraction and reverse transcription (RT)
Total RNA was isolated using TRIzol reagent (Invitrogen, Grand
sland, NY, USA) according to the manufacturer’s instructions.
ntegrity of the RNA was analyzed on agarose gels by staining with
elRed (Biotium, Hayward, CA, USA). 2 g of total RNA was reverse
ranscribed using RevertAid H Minus Reverse Transcriptase and
andom Hexamer Primers following the manufacturer’s protocol
Fermentas, Ontario, Canada).
.3. Quantitative real time RT-PCR
Quantitative real time RT-PCR (qRT-PCR) was performed as
escribed before [13]. We  normalized expression of the target
enes to the expression of the housekeeping gene Beta-2-
icroglobulin (B2M) and set relative to the calibrator (total
uman RNA, Clontech, Mountain View, CA, USA) to calculate rel-
tive expression with the Ct method. Sequences for B2M
14], CYP24A1 [15], CYP27B1 [15], and cytochrome P450 3A4
CYP3A4) [16] have been described previously. Primer sequences
or insulin-like growth factor binding protein (IGFBP3) were:
orward: CAGAATATGGTCCCTGCCG; reverse: GGGACTCAGCA-
ATTGAGG; COX-2: forward: GCCCTTCCTCCTGTGCCT; reverse:
AGGAAGCTGCTTTTTACCTTTG; 15-PGDH: forward: TGCTTCAAAG-
ATGGCATAG; reverse: AACAAAGCCTGGACAAATGG. Transient
eceptor potential cation channel, subfamily V, member 6 (TRPV6)try & Molecular Biology 144 (2014) 91–95
mRNA expression was determined using TaqMan Gene Expression
Assay (Cat. # 4331182, Life Technologies, Carlsbad, CA, USA).
2.4. Statistical analysis
We  used SPSS statistics package, version 18.0 for statistical anal-
ysis and GraphPadPrism 5.0 for drawing the ﬁgures. We performed
one-way ANOVA on log-transformed data with Tukey’s post hoc
test for multiple comparisons.
3. Results
3.1. Regulation of CYP24A1 and CYP27B1 expression by 1,25-D3,
TNF˛, and IL-6
As expected, treatment of COGA-1A cells with 1,25-D3 led to
a marked increase in the expression of the vitamin D degrading
enzyme CYP24A1 (15.000-fold increase after 6 h compared with
control) but the expression of the vitamin D activating enzyme
CYP27B1 remained constant (Fig. 1A and B). IL-6 treatment for 12 h
increased CYP24A1 expression almost three times. TNF upregu-
lated CYP24A1 expression 1.7-fold after 6 h, however, the increase
did not reach statistical signiﬁcance (Fig. 1A).
TNF reduced mRNA expression of the 1,25-D3 synthesizing
enzyme CYP27B1, both alone and in combination, at all time-
points. After 24 h the effect of TNF alone became highly signiﬁcant,
reducing CYP27B1 levels to 46% of the vehicle control. At earlier
time-points, only the combination with IL-6 was highly effective
and reduced CYP27B1 expression by 60% after 6 h and 12 h (Fig. 1B).
3.2. Effect of 1,25-D3, IL-6, and TNF  ˛ on expression of the vitamin
D target genes CYP3A4, TRPV6, IGFPB3, COX-2, and 15-PGDH
1,25-D3 increased CYP3A4 mRNA expression after 6 h 2.5-fold,
but the expression of TRPV6 remained unchanged. IL-6 treatment
has not affected CYP3A4 or TRPV6 expression at any time-point.
Surprisingly, treatment with TNF had a strong effect on expres-
sion of the vitamin D target genes CYP3A4 and TRPV6. It increased
CYP3A4 expression even more than 1,25-D3 treatment already after
6 h, irrespective whether it was applied alone (3.5-fold increase)
or in combinations. After 12 h, the increase was  only 2.8-fold,
returning to normal after 24 h (Fig. 1C). In contrast, expression
of TRPV6 was  strongly inhibited by TNF in all combinations at
all time-points with a maximal reduction after 12 h (28% of the
vehicle-treated control, Fig. 1D). Neither 1,25-D3, nor IL-6 or TNF
affected IGFPB3 expression in these cells (data not shown).
COX-2 and 15-PGDH expression was unresponsive to 1,25-D3
treatment in COGA-1A cells. IL-6 reduced 15-PGDH mRNA expres-
sion after 24 h by 41%, but had no inﬂuence on COX-2 expression. As
expected, TNF highly increased COX-2 expression (22-fold after
6 h) and decreased 15-PGDH mRNA levels (9-fold after 24 h) at all
investigated time-points both alone and in all treatment combina-
tions. 1,25-D3 was  able to reduce TNF-induced COX-2 expression
after 12 h by 37%. This inhibitory effect was lost when IL-6 was also
added to the TNF and 1,25-D3 treatment. Interestingly, the combi-
nation of 1,25-D3 and IL-6 led to a 44% downregulation of 15-PGDH
mRNA level after 12 h, whereas COX-2 expression remained stable
(Fig. 1E and F).
4. DiscussionThe anti-inﬂammatory effects of 1,25-D3 on IBD have been
studied extensively [7,17], however, whether activation and degra-
dation of vitamin D is impaired by an existing inﬂammation is
not yet clear. In this study, we  show for the ﬁrst time that TNF
D.M. Hummel et al. / Journal of Steroid Biochemistry & Molecular Biology 144 (2014) 91–95 93
A CYP2 4A1
B CYP27B1
C CYP 3A4
D TRPV 6
E COX-2
F 15 -PGDH
Fig. 1. Impact of 1,25-D3, IL-6, and TNF on CYP24A1, CYP27B1, CYP3A4, TRPV6, COX-2, and 15-PGDH expression. Cells were treated with 1,25-D3,  IL-6, TNF, and com-
binations of these compounds for 6 h, 12 h, and 24 h. mRNA expression of CYP24A1 (A), CYP27B1 (B), CYP3A4 (C), TRPV6 (D), COX-2 (E), and 15-PGDH (F) was assessed by
qRT-PCR. Each experiment was set relative to the vehicle control. Columns represent mean of 3 independent experiments, bars indicate SEM. Asterisks indicate statistical
signiﬁcant difference compared with vehicle control (*p < 0.05, **p < 0.01, ***p < 0.001).
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igniﬁcantly reduced CYP27B1 mRNA expression and expression of
he calcium ion channel TRPV6 in colorectal cancer cells. Whether
his reduces the capacity of the cells to activate vitamin D needs to
e proven.
The vitamin D degrading enzyme CYP24A1 is one of the main
arget genes of 1,25-D3. Overexpression of this enzyme likely leads
o insensitivity of the tissue toward 1,25-D3, limiting its anti-
roliferative and pro-apoptotic functions [18]. We  have shown
reviously, that both CYP24A1 expression and activity in COGA-
 cells is highly inducible by 1,25-D3 [19]. In our experiments,
YP24A1 was massively induced already after 6 h of treatment
ith 1,25-D3. This induction decreased with time but remained
ore than 35-fold higher even after 24 h treatment. As CYP24A1
xpression is paralleled with high enzymatic activity, this would
xplain the lack of an 1,25-D3 effect on the other known VDR tar-
et genes such as TRPV6 and IGFBP3. We  also observed a slight
ncrease in CYP24A1 expression after treatment with the inﬂam-
atory cytokines. Whether such a 2–3-fold increase in CYP24A1
RNA expression has any physiological meaning, remains ques-
ionable.
Several studies reported downregulation of CYP27B1 promoter
ctivity and mRNA expression upon treatment with 1,25-D3, how-
ver, data are inconsistent and seem to depend on tissue type
nd state of cell differentiation [20,21]. In the COGA-1A cells,
YP27B1 mRNA expression remained constant after 1,25-D3 treat-
ent, TNF, however, reduced CYP27B1 expression signiﬁcantly.
he human CYP27B1 promoter has numerous NFB-binding sites
22]. Ebert et al. have shown that upon NFB-binding, the activity
f the CYP27B1 promoter strongly decreased [23]. We  are the ﬁrst
o show in a colon cancer cell line, that TNF inhibits CYP27B1 tran-
cription. Whether this is mediated by NFB needs to be proven.
ombining TNF with IL-6 repressed further CYP27B1 expression,
uggesting an interplay of these two cytokines in regulation of the
itamin D system. In patients with Crohn’s disease as well as in a
ouse model of chemically induced inﬂammatory bowel disease,
YP27B1 expression was enhanced in granulomatous or lymphoid
issue. It is likely that it serves as a defense mechanism, since
YP27B1 knockout animals have more severe symptoms [24,25].
To evaluate whether increased CYP24A1 expression leads to
iminished VDR signaling, we analyzed mRNA expression of sev-
ral known 1,25-D3 target genes, namely CYP3A4 [9], TRPV6 [10],
nd IGFBP3 [11].
CYP3A4 is one of the most important drug-metabolizing
nzymes in humans, and its expression can be induced by 1,25-D3;
his enzyme is also able to degrade 1,25-D3 [26]. In our experi-
ents, 1,25-D3 treatment increased CYP3A4 levels, however, this
ffect was lost after 24 h. Interestingly, after 6 h, CYP3A4 expres-
ion was stronger enhanced by TNF than by 1,25-D3. This rapid
nduction suggests a direct, probably NFB-dependent induction
f CYP3A4 transcription. In several previous studies CYP3A4 is
ather inhibited by TNF. In primary human hepatocytes TNF-
ependent NFB activation released the PXR–RXR-complex from
he CYP3A4 promoter, suppressing CYP3A4 transcription [27]. In
ur study, all treatments in which 1,25-D3 or TNF were present
ed to an upregulation of CYP3A4 after 6 h. We  hypothesize that the
pregulation of CYP3A4 by TNF in COGA-1A cells might be medi-
ted by direct binding of activated NFB to its two  putative binding
ites located 2000 basepairs upstream of the start codon [28,29].
TRPV6 is a calcium ion channel essential for the absorption of
alcium from the intestinal lumen regulated by 1,25-D3 treatment
n most CRC cells [30]. Surprisingly, in our cell line, treatment with
,25-D3 had no effect on TRPV6 expression. Huybers et al. observed
hat in TNFARE/+ mice, which are characterized by enhanced TNF
erum levels, TRPV6, calbindin D9k, and PMCA1b were downregu-
ated [31]. Similarly, in our cells TRPV6 levels were affected only by
NF. Our data suggest that inﬂammatory cytokines might impair
[try & Molecular Biology 144 (2014) 91–95
calcium uptake by reducing TRPV6 levels during intestinal inﬂam-
mation.
1,25-D3 plays a pivotal role in regulation of the prostaglandin
pathway, affecting both PGE2 synthesis by inhibition of COX-2
expression, as well as its degradation by stimulation of 15-PGDH
expression [32,33]. In our cells, 1,25-D3 inhibited TNF-induced
upregulation of COX-2 after 12 h. Besides this effect, treatment with
1,25-D3 did not alter expression of COX-2 or of 15-PGDH, suggest-
ing that the inﬂuence of 1,25-D3 on the PGE2-pathway is time- and
tissue-dependent.
We conclude that inﬂammation interferes with the vitamin D
metabolism. We  could show that the proinﬂammatory cytokines
TNF and IL-6 inhibited the expression of the vitamin D activating
gene CYP27B1 in the COGA-1A cell line. The inhibitory effect of
TNF on CYP27B1 and TRPV6 expression in colon cancer cells might
alter calcium uptake in the inﬂamed intestine.
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